复宏汉霖获卫材株式会社授权 开发、生产及商业化汉斯状

美股速递
Feb 05

上海复宏汉霖生物技术股份有限公司宣布,已获得日本卫材株式会社(Eisai Co)的授权,将负责开发、生产及商业化其创新药物汉斯状(Hansizhuang)。此次合作标志着双方在生物医药领域的战略协同进一步深化,有望加速该药物在全球市场的布局进程。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10